YY201 for advanced solid tumors and blood cancers
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug, YY201, that targets a protein called STAT3, which may help certain advanced solid tumors and blood cancers. It is for people who have tried standard treatments without success.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 80 years old
- You have advanced solid tumor or blood cancer that has not responded to or cannot have standard treatment
- You are well enough to do daily activities (ECOG score 0 or 1)
- Your cancer is measurable on scans (for solid tumors) or has specific features (for certain blood cancers)
- You have adequate organ function (kidney, liver, bone marrow) as shown by blood tests
- You are willing to use effective birth control if you are able to have children
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests YL201 in people with advanced (late-stage) solid cancers when usual treatments don’t work or can’t be tolerated. The study looks at how the treatment is given, how safe it is, and how well it can shrink tumors.
This Phase 1 study tests PYX-201 in people with advanced (grown or spread) solid cancers to see if it is safe and how it works. You may qualify if your cancer has had up to a couple of prior treatments and you can safely take study medicines and undergo required testing like a tumor biopsy.
This study tests a new experimental drug (NWY001) for people with advanced solid tumors that have stopped responding to standard treatments. It is a phase 1 trial, meaning it is early research to find the right dose and check for side effects.
This trial tests a new drug called HS-20105 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
This trial tests a new drug called YL202 for people with advanced breast cancer. It is for those who have already tried certain targeted treatments (HER2 or TROP2 antibody-drug conjugates) and they stopped working. The goal is to see if YL202 can help shrink tumors or slow cancer growth.
This trial tests a new drug called JYP0035 alone in people with advanced solid tumors. It aims to see if the drug is safe and effective.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.